Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.516 estudios en Cancer (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS Rochester, Minn., Mankato, Minn., La Crosse, Wis., Eau Claire, Wis. The purpose of this study is to examine how well ascorbic acid and combination chemotherapy work in treating patients with lymphoma that has come back or does not respond to therapy. Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may work better at treating lymphoma. In the Clonal Cytopenia of Undetermined Significance (CCUS) Cohort D, we want to find out if ascorbic acid will improve blood counts so fewer transfusions are required and there is a less likely chance the patient will develop myelodysplastic syndrome (MDS) or other related myeloid malignancies. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Jacksonville, Fla. UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion for patients once every four weeks. Patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer expressing high levels of NaPi2b. A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness. (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis Scottsdale/Phoenix, Ariz. The purpose of this study is to investigate CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM. (ASM), System Mastocytosis (SM) with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). Specialty Compared to Oncology Delivered Palliative Care for Treating Acute Myeloid Leukemia Rochester, Minn. The purpose of this study is to evaluate whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML). A Study to Develop Liquid Biopsy for Pediatric Brain Tumor Patients Rochester, Minn. The purpose of this study is to confirm detection of the H3K27M mutation in patient biofluids (CSF, blood, urine, saliva) and uncover the molecular histone (alkaline protein) profile of H3K trimethylation and H3S phosphorylation in the circulating nucleosomes isolated from the biofluids of patients with H3K27M tumors. A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to investigate the antitumor activity of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced solid tumors including: Cohort A: Colorectal cancer (CRC); Cohort B: Gastric and gastroesophageal junction (GEJ) cancer; Cohort C: Triple-negative breast cancer (TNBC); Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer). Circulating Tumor Nucleic Acids to Monitor Treatment Response in Metastatic Melanoma Patients Scottsdale/Phoenix, Ariz. This project will investigate whether the analysis of nucleic acids circulating in the blood from tumors can allow real-time monitoring of treatment response to targeted therapy and immunotherapy for patients who have stage IV metastatic melanoma. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia Rochester, Minn. The purpose of this study is is to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline treatment. A Registry Called Every Child for Collecting Data and Biology Specimens on Younger Patients with Cancer Rochester, Minn. The purpose of this registry called Every Child, is to collect data and biospecimens from multiple body sources for younger patients with cancer over time. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 3636 Ir a página 3737 Ir a página 3838 Ir a página 3939 Ir a página 4040 SiguientePróxima página Profesionales médicos Cancer clinical-trials